雙塔食品(002481.SZ):子公司與Beyond Meat籤銷售合同 首次向其直接銷售285噸豌豆蛋白
格隆匯2月25日丨雙塔食品(002481.SZ)公佈,公司全資子公司君邦商貿於2月24日(美國時間週一)與Beyond Meat簽署了85%豌豆蛋白銷售合同,首批豌豆蛋白採購量為628320磅(約285噸)。該銷售合同為Beyond Meat首次直接向君邦商貿採購豌豆蛋白原料。
Beyond Meat是一家美國素食肉生產商,於2009年創立,曾獲得比爾·蓋茨投資,其產品在全球3.2萬個網點銷售。2019年5月,公司登陸納斯達克,股票代碼為BYND。之前君邦商貿通過經銷商向Beyond Meat間接銷售豌豆蛋白。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.